Results 171 to 180 of about 138,235 (308)

Plerixafor plus granulocyte colony-stimulating factor for patients with non-Hodgkin lymphoma and multiple myeloma: Long-term follow-up report [PDF]

, 2018
Bolwell, Brian, Cheverton, Peter D, DiPersio, John F, Horwitz, Mitchell E, Kaufman, Jonathan L, Maziarz, Richard T, McCarty, John M, Micallef, Ivana N, Nademanee, Auayporn P, Stadtmauer, Edward A, Stiff, Patrick J, Struijs, Martin, Vargo, Rita   +12 more
core   +2 more sources

A Rare Case of Non-Hodgkin Lymphoma of the Tracheobronchial Tree. [PDF]

Cureus
Jain NP, Hirani N, Khilnani AK, Oza C, Patel K.   +4 more
europepmc   +1 more source

Exploiting ALK inhibition in anaplastic large cell lymphoma: Biological rationale and therapeutic integration

British Journal of Haematology, EarlyView.
Summary Mature T‐cell lymphomas comprise a heterogeneous group of aggressive non‐Hodgkin lymphomas with limited therapeutic options in the relapsed or refractory setting. Among them, anaplastic lymphoma kinase (ALK)‐positive anaplastic large cell lymphoma (ALCL) represents a biologically distinct subtype driven by constitutive activation of ALK fusion ...
Santino Caserta, Enrica Antonia Martino, Mamdouh Skafi, Maria Eugenia Alvaro, Antonella Bruzzese, Nicola Amodio, Marco Fiorillo, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +13 more
wiley   +1 more source

Type 2 diabetes and risk of non-Hodgkin lymphoma and multiple myeloma: a pooled analysis. [PDF]

JNCI Cancer Spectr
Ardisson Korat AV, Deubler EL, Bertrand KA, Teras LR, Lacey JV, Patel AV, Rosner BA, Shu YH, Zhong C, Wang SS, Birmann BM, Chao CR.   +11 more
europepmc   +1 more source

Checkpoint inhibitors, obinutuzumab plus PET‐adapted ultra‐low dose nodal radiotherapy yield high efficacy in treatment‐naïve follicular lymphoma: Results from the phase II ‘FLUORO’ study

British Journal of Haematology, EarlyView.
Summary Follicular lymphoma (FL) first‐line chemoimmunotherapy yields high efficacy but serious toxicity in 65% of patients. In high tumour burden treatment‐naïve FL, we aimed to exploit known immunostimulatory and cytotoxic properties of combination checkpoint inhibition (atezolizumab) and obinutuzumab (6 cycles) with positron emission tomography (PET)
Arina Martynchyk, Geoffrey Chong, Richard Khor, Denise Lee, Sze Ting Lee, Andrew M. Scott, Anneke C. Grobler, Belinda A. Campbell, Thanuja Thachil, Kate Manos, Genevieve Douglas, Alexandra Romano, Jodie B. Palmer, Melinda Burgess, Colm Keane, Eliza A. Hawkes   +15 more
wiley   +1 more source

Advancing the Diagnosis of Non-Hodgkin Lymphoma Through Next-Generation Sequencing in Developing Countries: An Evaluation of Progress-A Narrative Review. [PDF]

Health Sci Rep
Saeidnia M, Shokri M, Nourmohammadi H, Radmehr S, Babashahi M, Moradi M, Karimian M, Panji M, Motevaseli E.   +8 more
europepmc   +1 more source

Incidence of severe COVID‐19 in patients with chronic lymphocytic leukaemia or indolent B‐cell non‐Hodgkin lymphoma who received vaccination and pre‐exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi

British Journal of Haematology, EarlyView.
Gian Matteo Rigolin, Stefano Soddu, Riccardo Dondolin, Anna Maria Frustaci, Ilaria Scortechini, Francesca Romana Mauro, Francesco Angotzi, Marina Motta, Lydia Scarfò, Andrea Mengarelli, Annamaria Giordano, Sara Martinelli, Caterina Patti, Paolo Sportoletti, Alessandro Sanna, Nilla Maschio, Rossella Riccioni, Clara Virginia Viganò, Agostino Tafuri, Alfonso Piciocchi, Paola Fazi, Stefano Luminari, Andrés J. M. Ferreri, Guido Gini, Paolo Ghia, Antonio Cuneo   +25 more
wiley   +1 more source

Deciphering the full spectrum of Castleman diseases based on a cohort of 700 patients in a western country

British Journal of Haematology, EarlyView.
The spectrum of Castleman diseases has expanded over the past three decades. The phenotype of the diseases varies not only among the three major types but also according to the patient ancestry. Summary Under the Castleman disease (CD) eponym, three distinct diseases sharing common pathological features have been described over time.
Eric Oksenhendler, Marion Malphettes, Véronique Meignin, David Boutboul, Lionel Galicier   +4 more
wiley   +1 more source

A Milky Mystery: Chylothorax Unmasking Non-Hodgkin Lymphoma. [PDF]

Cureus
Tangutoori S, Gullapalli D, Kommineni SS, Gudipati MK, Depa J, Gaddam M, Ganti SS.   +6 more
europepmc   +1 more source

Decreased renal function predicts severe cytokine release syndrome after CAR‐T‐cell therapy for large B‐cell lymphoma

British Journal of Haematology, EarlyView.
Summary Cytokine release syndrome (CRS) remains a major toxicity of chimeric antigen receptor (CAR) T‐cell therapy in large B‐cell lymphoma (LBCL), and robust pre‐infusion predictors are needed for risk‐adapted management. We retrospectively analysed LBCL patients in the Japanese nationwide registry who underwent CD19 CAR‐T‐cell therapy between 2019 ...
Yasuyuki Arai, Tomoyasu Jo, Takayuki Sato, Masatoshi Sakurai, Daisuke Kaji, Toshio Kitawaki, Kazuyuki Shimada, Tatsu Shimoyama, Satoshi Yoshihara, Shinichi Makita, Nobuharu Fujii, Go Yamamoto, Keisuke Kataoka, Emiko Sakaida, Hideki Goto, Yasuhiro Nakashima, Akiyo Yoshida, Yoshihiro Umezawa, Haryoon Kim, Motohiro Kato, Yoshiko Atsuta, Koji Kato   +21 more
wiley   +1 more source